Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Vistagen Therapeutics Inc (VTGN)

Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update Business Wire - Mon Jun 15, 3:30PM CDT

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month Completed...

VTGN : 0.7020 (+13.85%)
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder Business Wire - Tue Jun 9, 7:30AM CDT

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...

VTGN : 0.7020 (+13.85%)
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm PR Newswire - Mon Jun 1, 1:40PM CDT

NEW YORK , June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ:...

VTGN : 0.7020 (+13.85%)
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference Business Wire - Wed May 27, 7:30AM CDT

Vistagen , a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called...

VTGN : 0.7020 (+13.85%)
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer Business Wire - Tue May 19, 7:30AM CDT

Dr. Angelov brings extensive industry experience across multiple therapeutic areas

VTGN : 0.7020 (+13.85%)
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference Business Wire - Thu May 14, 7:30AM CDT

Vistagen , a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called...

VTGN : 0.7020 (+13.85%)
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Business Wire - Tue May 12, 6:30AM CDT

Fasedienol nasal spray has been well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use in daily life for up to 12 months ...

VTGN : 0.7020 (+13.85%)
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder Business Wire - Fri May 8, 6:30AM CDT

Topline results for the randomized portion of PALISADE-4 are expected in the second quarter of 2026

VTGN : 0.7020 (+13.85%)
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop PR Newswire - Tue Apr 28, 8:00AM CDT

SAN FRANCISCO , April 28, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Vistagen Therapeutics, Inc. (NASDAQ: VTGN) investors that the firm is investigating potential legal claims arising...

VTGN : 0.7020 (+13.85%)
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause Business Wire - Wed Apr 22, 7:30AM CDT

Vistagen (Nasdaq: VTGN) , a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...

VTGN : 0.7020 (+13.85%)

Barchart Exclusives

Why Verizon, AT&T, and T-Mobile Should Be Terrified of Elon Musk’s Next Move Barchart - Sun Jun 28, 3:30PM CDT
SpaceX is reportedly preparing its next major Starlink expansion, a move that could reshape the telecom industry. Here's what it could mean for the company's growth—and for incumbent wireless providers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.